DNAJC5, also known as Cysteine String Protein (CSP), is a synaptic vesicle-associated molecular chaperone that plays a critical role in maintaining neuronal homeostasis. The protein is encoded by the DNAJC5 gene located on chromosome 10q24.32 and is essential for synaptic vesicle function, protein quality control, and neuronal survival. CSP is a member of the DnaJ/Hsp40 co-chaperone family and is characterized by a unique cysteine-rich "string" domain at its C-terminus that undergoes palmitoylation for membrane anchoring[1].
Mutations in DNAJC5 cause autosomal dominant adult-onset neuronal ceroid lipofuscinosis (ANCL), a rare neurodegenerative lysosomal storage disorder. Additionally, CSP has been increasingly recognized for its involvement in Parkinson's disease, Alzheimer's disease, and other neurodegenerative conditions[2][3].
| Attribute | Value |
|---|---|
| Protein Name | Cysteine String Protein (CSP) |
| Gene Symbol | DNAJC5 |
| UniProt ID | Q9H3K2 |
| NCBI Gene ID | 80315 |
| Protein Family | DNAJ/Hsp40 co-chaperone family |
| Protein Length | 198 amino acids |
| Molecular Weight | ~22.4 kDa |
| Subcellular Location | Synaptic vesicles, endoplasmic reticulum, mitochondria (stress-induced) |
| Brain Expression | High: cortex, hippocampus, basal ganglia, cerebellum |
| Associated Diseases | ANCL, Parkinson's Disease, Alzheimer's Disease, ALS |
CSP possesses a distinctive domain architecture that enables its diverse cellular functions:
The N-terminal J-domain is the hallmark of Hsp40 family proteins. This approximately 70-amino acid domain contains the highly conserved HPD motif (His-Pro-Asp) that is essential for interacting with and stimulating the ATPase activity of Hsp70 chaperones[4]. The J-domain recruits Hsp70 (particularly Hsc70/Hspa8) to assist in protein folding, refolding of misfolded proteins, and disassembly of protein complexes. Mutations in the J-domain (such as C105F) disrupt this interaction and cause ANCL[2:1].
The central glycine-rich region provides structural flexibility and mediates interactions with various client proteins. This region contains multiple serine/threonine phosphorylation sites that regulate CSP function. Phosphorylation by casein kinases and other kinases modulates CSP's interaction with downstream effectors[5].
The C-terminal cysteine string domain contains 13 cysteine residues, 10 of which undergo palmitoylation—a reversible lipid modification that anchors CSP to synaptic vesicle membranes[6]. The palmitoylated cysteine string targets CSP to synaptic vesicles, where it constitutes up to 1% of total synaptic vesicle protein. The cysteine string is essential for membrane association but can be dynamically depalmitoylated and repalmitoylated in response to neuronal activity.
CSP functions as a co-chaperone for Hsp70 proteins through its J-domain[4:1]:
The CSP-Hsp70 complex handles:
Beyond chaperone activity, CSP plays direct roles in synaptic transmission[7][8]:
SNARE Complex Assembly: CSP co-assembles with the SNARE machinery and is essential for synaptic vesicle fusion. CSP knockout mice show severely impaired neurotransmitter release.
Vesicle Priming: CSP participates in the priming step that prepares vesicles for Ca²⁺-triggered fusion.
Vesicle Recycling: CSP regulates clathrin-mediated endocytosis during synaptic vesicle recycling.
Neurotransmitter Release: Loss of CSP function leads to impaired synaptic vesicle cycling and reduced neurotransmitter release.
CSP regulates calcium release from the endoplasmic reticulum through interactions with ryanodine receptors (RyRs)[9]:
Under oxidative stress conditions, CSP translocates to mitochondria where it provides protective functions[10][11]:
CSP is highly expressed throughout the central nervous system:
| Brain Region | Expression Level | Cell Types |
|---|---|---|
| Cerebral Cortex | High | Layer 5 pyramidal neurons |
| Hippocampus | High | CA1-CA3 pyramidal cells, dentate gyrus granule cells |
| Basal Ganglia | High | Striatal medium spiny neurons, substantia nigra pars compacta |
| Cerebellum | High | Purkinje cells, granule cells |
| Brainstem | Moderate | Motor nuclei, reticular formation |
Within neurons, CSP localizes to:
Dominant mutations in DNAJC5 cause ANCL (Kufs disease type A), a rare neurodegenerative disorder characterized by[2:2][13]:
| Feature | Details |
|---|---|
| Inheritance | Autosomal dominant |
| Age of Onset | 30-50 years |
| Clinical Features | Progressive dementia, motor dysfunction (ataxia, parkinsonism), seizures, visual loss |
| Neuropathology | Neuronal loss and gliosis, ceroid lipopigment accumulation, subcortical/cortical atrophy |
| Treatment | No disease-modifying therapies approved; experimental approaches include pharmacological chaperones and gene therapy |
| Mutation | Type | Effect on Protein |
|---|---|---|
| C105F | Missense | Disrupts J-domain Hsp70 interaction |
| L116del | In-frame deletion | Impairs chaperone activity |
| D205H | Missense | Reduces protein stability |
| G219W | Missense | Dominant-negative effect |
CSP has been increasingly implicated in Parkinson's disease pathogenesis through multiple mechanisms[14][15]:
Alpha-Synuclein Interaction: CSP regulates alpha-synuclein aggregation and clearance through the autophagy-lysosome pathway. CSP deficiency enhances alpha-synuclein oligomerization.
Synaptic Dysfunction: Loss of CSP function leads to impaired synaptic vesicle cycling, a hallmark of early PD.
Protein Quality Control Impairment: CSP mutations compromise the cellular protein quality control system, leading to accumulation of damaged proteins.
Oxidative Stress Vulnerability: CSP-deficient neurons show increased vulnerability to oxidative stress, a key pathogenic factor in PD.
Mitochondrial Dysfunction: CSP mutations impair mitochondrial quality control and function.
CSP is implicated in Alzheimer's disease through several mechanisms[16]:
Pharmacological chaperones that stabilize CSP structure are being investigated for ANCL treatment[17][18]:
| Compound | Mechanism | Status |
|---|---|---|
| 4-Phenylbutyric acid (PBA) | Chemical chaperone, protein stabilization | Preclinical |
| Sodium butyrate | Histone deacetylase inhibitor, CSP upregulation | Preclinical |
| Geranylgeranylacetone | Hsp70 activator | Experimental |
AAV-mediated gene delivery of wild-type DNAJC5 represents a promising therapeutic approach:
Small molecules targeting alpha-synuclein aggregation may benefit CSP-deficient states:
| Model | Characteristics | Research Use |
|---|---|---|
| CSPα knockout mice | Neonatal lethality | Understanding essential functions |
| Conditional KO | Adult-onset neurodegeneration | PD/AD modeling |
| Transgenic overexpression | Protective in some contexts | Therapeutic screening |
| Knock-in mutations | ANCL modeling | Mutation-specific effects |
Greaves J, et al (2008). Palmitoylation of cysteine-string protein. Biochem J, 413(3), 479-491
García-Partida JA, et al (2020). DNAJC5 in alpha-synuclein pathology. Mov Disord, 35(10), 1783-1794
Cadzow M, et al. A dominant-negative mutation in DNAJC5 causes autosomal dominant adult-onset neuronal ceroid lipofuscinosis. 2016. ↩︎ ↩︎ ↩︎
Burgoyne RD, et al. Cysteine string protein (CSP) and its role in neurodegeneration. 2015. ↩︎
Chamberlain LH, Burgoyne RD. The cysteine-string protein function. 1997. ↩︎ ↩︎
Nie Z, et al. Phosphorylation of cysteine string protein. 1999. ↩︎
Greaves J, et al. Palmitoylation of cysteine-string protein. 2008. ↩︎
Sharma M, et al. CSPalpha knockout mice display progressive neurodegeneration. 2012. ↩︎
Kim Y, et al. CSP in synaptic vesicle recycling. 2018. ↩︎
Wang J, et al. Calcium release from ryanodine receptors is modulated by cysteine string protein. 2011. ↩︎
Chen L, et al. Mitochondrial targeting by cysteine string protein during oxidative stress. 2010. ↩︎
Solesio ME, et al. The role of cysteine string protein in mitochondrial dynamics and function. 2021. ↩︎
Johnson JN, et al. ER-mitochondria contact sites in neurodegeneration. 2019. ↩︎
Donaghy C, et al. Adult-onset neuronal ceroid lipofuscinosis associated with DNAJC5 mutations. 2015. ↩︎
García-Partida JA, et al. DNAJC5 in alpha-synuclein pathology. 2020. ↩︎
Zhang X, et al. The function of cysteine string protein (CSP) in neurodegeneration. 2018. ↩︎
Moussa CE, et al. Cysteine string protein in Alzheimer's disease. 2019. ↩︎
Muñoz A, et al. Chaperone-based therapeutic strategies in neurodegenerative diseases. 2019. ↩︎
Tóth G, et al. Targeting Hsp70 and DNAJC5 for neurodegeneration therapy. 2019. ↩︎